all report title image

Middle East and Asia Injectable Drugs Market, By Product Type (Pre-filled Syringes, Auto-injectors, Pre-filled Pens, Pre-mixed IV Bags, Others), By Drug Class (Anesthesia, Antibiotics, Antidotes, Antiemetic, Anti-infective, Anti-thrombolytic, Muscle Relaxant, Non Opioids, Opioids, Sedatives, and Others), By Route of Administration (Intramuscular (IM), Intravenous (IV), Subcutaneous (SC), and Others (Epidural and Intrathecal)), By End Users (Hospitals, Clinics, and Ambulatory Surgery Centers)

  • Published In : 13 May, 2026
  • Code : CMI4891
  • Pages :155
  • Formats :
      Excel and PDF
  • Industry : Medical Devices
  • 역사적 분포 범위 : 2020 - 2024
  • 기준 연도 : 2025
  • 예상 연도 : 2026
  • 예측 기간 : 2026 - 2033

Injectable drug delivery is considered as the most effective route of administration for the effective delivery of drugs to the targeted site. Injectable delivery facilitates rapid absorption of drug from various route of administration such as subcutaneous, intravenous, and intramuscular. Injectable delivery increases the bioavailability of the drug at the systemic circulation. The increasing prevalence of chronic diseases, technological advancements, demand for individual therapy, awareness regarding drug metabolism among the population, and requirement of controlled drug release are the major factors driving the growth of the Middle East and Asia injectable drugs market.

Middle East and Asia injectable drugs market is estimated to be valued at US$ 4,15,000 Mn in 2021 and is expected to increase to US$ 7,23,164 Mn by 2028, witnessing a CAGR of 8.2% during the forecast period.

Market Dynamics

Increase in technology advancement, increasing government initiatives in healthcare sector of Middle East, innovations and ongoing R&Ds on injectable drug delivery systems and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Middle East and Asia injectable drugs market.

As per the article Bevan Brittan, 2020, The Middle East is seeing a boom in healthcare sector. Aging populations, lengthening life expectations, and different lifestyle are the factors driving the market growth. The opportunities are leading to new models of care and out of hospital facilities because of the focus on prevention and not just simple treatment. Encompassing the primary, community and secondary care, the Saudi Arabia has embarked to build a new healthcare system.

Key features of the study

  • This report provides in-depth analysis of the Middle East and Asia injectable drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Middle East and Asia injectable drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Kalbe Farma, Takeda pharmaceuticals Co. Ltd., Livzon Pharmaceutical Group, Inc., Sun Pharmaceutical Industries, Ltd., Pfizer, Inc., Sanofi, Novartis, Tabuk, Novo Nordisk, GlaxoSmithKline plc, AstraZeneca, and Gerresheimer AG
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The Middle East and Asia injectable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Asia injectable drugs market

 Market Segmentation

  • By Product Type (Revenue, USD Bn, 2021-2033)
    • Pre-filled Syringes
      • Vaccines
      • Blood Stimulants
      • Biologics
      • Others
    • Auto-injectors
    • Pre-filled Pens
    • Pre-mixed IV Bags
      • Sedative Products (Sedation)
      • Anesthesia Products (Anesthesia)
      • Pain Management Products (Post-operative analgesic pain management)
      • Chemotherapy Products (Chemotherapy)
      • Antibacterial Products (Infectious diseases)
      • Electrolyte and Nutrition Products (Electrolyte and Nutrition)
    • Others
  • By Route of Administration (Revenue, USD Bn, 2021-2033)
    • Intramuscular (IM)
    • Intravenous (IV)
    • Subcutaneous (SC)
    • Others (Epidural and Intrathecal)
  • By Drug Class (Revenue, USD Bn, 2021-2033)
    • Anesthesia
    • Antibiotics
    • Antidotes
    • Antiemetic
    • Anti-infective
    • Anti-thrombolytic
    • Muscle Relaxant
    • Non Opioids
    • Opioids
    • Sedatives
    • Others
  • By End User (Revenue, USD Bn, 2021-2033)
    • Hospitals
    • Clinics
    • Ambulatory Surgery Centers
  • By Region (Revenue, USD Bn, 2021-2033)
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Key Players
    • Kalbe Farma
    • Takeda pharmaceuticals Co. Ltd.
    • Livzon Pharmaceutical Group, Inc.
    • Sun Pharmaceutical Industries, Ltd.
    • Pfizer, Inc.
    • Sanofi
    • Novartis
    • Tabuk
    • Novo Nordisk
    • GlaxoSmithKline plc
    • AstraZeneca
    • Gerresheimer AG

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Product Type
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Drug Class
      • Market Snapshot, By End User
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Product Approval
    • Collaboration/Merge/Acquisition
    • Regulatory Landscape
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Epidemiology
    • Robust Pipeline Analysis
  4. Middle East and Asia Injectable Drugs Market, By Product Type, 2021 – 2033, (USD Bn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022– 2033
      • Segment Trends
    • Pre-filled Syringes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
      • Segment Trends
        • Vaccines
        • Blood Stimulants
        • Biologics
        • Others
    • Auto-injectors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Pre-filled Pens
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Pre-mixed IV Bags
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
      • Segment Trends
        • Sedative Products (Sedation)
        • Anesthesia Products (Anesthesia)
        • Pain Management Products (Post-operative analgesic pain management)
        • Chemotherapy Products (Chemotherapy)
        • Antibacterial Products (Infectious diseases)
        • Electrolyte and Nutrition Products (Electrolyte and Nutrition)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
  5. Middle East and Asia Injectable Drugs Market, By Route of Administration, 2021 – 2033, (USD Bn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022– 2033
      • Segment Trends
    • Intramuscular (IM)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Intravenous (IV)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Subcutaneous (SC)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Others (Epidural and Intrathecal)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
  6. Middle East and Asia Injectable Drugs Market, By Drug Class, 2021 – 2033, (USD Bn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022– 2033
      • Segment Trends
    • Anesthesia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Antibiotics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Antidotes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Antiemetic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Anti-infective
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Anti-thrombolytic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Muscle Relaxant
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Non Opioids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Opioids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Sedatives
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
  7. Middle East and Asia Injectable Drugs Market, By End User, 2021 – 2033, (USD Bn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022– 2033
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
    • Ambulatory Surgery Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
  8. Middle East and Asia Injectable Drugs Market, By Country, 2021 – 2033, (USD Bn)
    • Introduction
      • Market Share Analysis, By Region, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, For Regions, 2022–2033
      • Country Trends
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Asia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
    • Company Profile
      • Kalbe Farma
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Takeda pharmaceuticals Co. Ltd.,
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Livzon Pharmaceutical Group, Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Sun Pharmaceutical Industries, Ltd.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Sanofi
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Novartis
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Tabuk
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Novo Nordisk
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • GlaxoSmithKline plc
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • AstraZeneca
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Gerresheimer AG
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About Us
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2026 Coherent Market Insights Pvt Ltd. All Rights Reserved.